Afuresertib (GSK2110183) (C09-0735-480)

InformationAfuresertib (GSK2110183) is a potent, orally bioavailableAktinhibitor withKiof 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.TargetsAkt1 (Cell-free assay); Akt2 (Cell-free assay); Akt3 (Cell-free assay) 0.08 nM(Ki); 2 nM(Ki); 2.6 nM(Ki)In vitroAfuresertib inhibits the kinase activity of the E17K AKT1 mutant protein with EC50 of 0.2 nM. Afuresertib shows a concentration-dependent effect on multiple AKT substrate phosphorylation levels, including GSK3b, PRAS40, FOXO and Caspase 9. Overall 65% of the hematological cell lines are sensitive to afuresertib (EC50 < 1 μM). Among tested solid tumor cell lines, 21% have EC50 < 1 μM in response to afuresertib.In vivoMice bearing BT474 breast tumor xenografts are dosed with afuresertib (p.o.) at 10, 30 or 100 mg/kg daily which results in 8, 37 and 61% TGI, respectively. Mice bearing SKOV3 ovarian tumor xenografts are treated with 10, 30 and 100 mg/kg afuresertib which results in 23, 37 and 97% TGI, respectively.Cell Research(from reference)Cell lines：Hematological cell lines and solid tumor cell lines Concentrations：30 μM Incubation Time：72 h. Specification: 0.99 Molecular Formula: C18H17Cl2FN4OS Molecular Weight: 427.32 PubChem CID: 46843057 Isomeric SMILES: CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)N[C@@H](CC3=CC(=CC=C3)F)CN)Cl